Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with or without chemotherapy for advanced, recurrent, or persistent cervical cancer
ChiCTR1800014253Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Cervical Cancer (CC), sponsored by Shandong Cancer Hospital. Primary endpoints: progression-free survival, safety and 3 more. Started Feb 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800014253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014253.